81 related articles for article (PubMed ID: 6640539)
1. Light, fluorescent, and electron microscopic analysis of cultured breast tumor cells (T-47D) treated with 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride.
Tseng MT; Safa AR
Cancer Res; 1983 Dec; 43(12 Pt 1):5910-4. PubMed ID: 6640539
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
3. Activation of tumor-cytostatic macrophages with the antitumor agent 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazole-2-yl)hydrazone] dihydrochloride (bisantrene).
Wang BS; Lumanglas AL; Ruszala-Mallon VM; Durr FE
Cancer Res; 1984 Jun; 44(6):2363-7. PubMed ID: 6426780
[TBL] [Abstract][Full Text] [Related]
4. Growth and ultrastructural responses of T-47D human breast tumor cells to treatment with mitoxantrone.
Safa AR; Ballou RJ; Tseng MT
Cancer Detect Prev; 1985; 8(4):455-64. PubMed ID: 4053107
[TBL] [Abstract][Full Text] [Related]
5. Molecular pharmacology of the anthracycline drug 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (Cl 216,942).
Bowden GT; Garcia D; Peng YM; Alberts DS
Cancer Res; 1982 Jul; 42(7):2660-5. PubMed ID: 7083158
[TBL] [Abstract][Full Text] [Related]
6. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
7. Drug and hormone sensitivity of estrogen receptor-positive and -negative human breast cancer cells in vitro.
Goldenberg GJ; Froese EK
Cancer Res; 1982 Dec; 42(12):5147-51. PubMed ID: 7139616
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene).
Yap BS; Yap HY; Blumenschein GR; Bedikian AY; Pocelinko R; Bodey GP
Cancer Treat Rep; 1982 Jul; 66(7):1517-20. PubMed ID: 7093967
[TBL] [Abstract][Full Text] [Related]
9. Alteration of cell shape, adhesion, and lipid accumulation in human breast cancer cells (T-47D) by human prolactin and growth hormone.
Shiu RP; Paterson JA
Cancer Res; 1984 Mar; 44(3):1178-86. PubMed ID: 6692402
[TBL] [Abstract][Full Text] [Related]
10. Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy.
Lown JW; Hanstock CC; Bradley RD; Scraba DG
Mol Pharmacol; 1984 Jan; 25(1):178-84. PubMed ID: 6708933
[TBL] [Abstract][Full Text] [Related]
11. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
Powis G; Kovach JS
Cancer Res; 1983 Feb; 43(2):925-9. PubMed ID: 6848203
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting the sensitivity of T-47D human breast cancer cells to tamoxifen.
Reddel RR; Murphy LC; Sutherland RL
Cancer Res; 1984 Jun; 44(6):2398-405. PubMed ID: 6722780
[TBL] [Abstract][Full Text] [Related]
13. Low-energy-loss electron microscopy of doxorubicin in human breast cancer MCF-7 cells: localization by color.
Mhawi AA; Fernandes AB; Ottensmeyer FP
J Struct Biol; 2007 Apr; 158(1):80-92. PubMed ID: 17174106
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein mediates profound resistance to bisantrene.
Zhang XP; Ritke MK; Yalowich JC; Slovak ML; Ho JP; Collins KI; Annable T; Arceci RJ; Durr FE; Greenberger LM
Oncol Res; 1994; 6(7):291-301. PubMed ID: 7865904
[TBL] [Abstract][Full Text] [Related]
15. Influence of mitoxantrone on nucleic acid synthesis on the T-47D breast tumor cell line.
Safa AR; Chegini N; Tseng MT
J Cell Biochem; 1983; 22(2):111-20. PubMed ID: 6671991
[TBL] [Abstract][Full Text] [Related]
16. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
17. Phagocytosis, cellular distribution, and carcinogenic activity of particulate nickel compounds in tissue culture.
Costa M; Simmons-Hansen J; Bedrossian CW; Bonura J; Caprioli RM
Cancer Res; 1981 Jul; 41(7):2868-76. PubMed ID: 7248947
[TBL] [Abstract][Full Text] [Related]
18. Bisantrene, an active drug in patients with advanced breast cancer.
Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
[TBL] [Abstract][Full Text] [Related]
19. Analysis of methylglyoxal bis(guanylhydrazone)-induced alterations of hamster tumor mitochondria by correlated studies of selective rhodamine binding, ultrastructural damage, DNA replication, and reversibility.
Nass MM
Cancer Res; 1984 Jun; 44(6):2677-88. PubMed ID: 6722801
[TBL] [Abstract][Full Text] [Related]
20. Human corneal epithelial cell viability and morphology after dilute alcohol exposure.
Chen CC; Chang JH; Lee JB; Javier J; Azar DT
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2593-602. PubMed ID: 12147590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
